{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T10:18:31Z","timestamp":1717582711383},"reference-count":63,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[1997,3,1]],"date-time":"1997-03-01T00:00:00Z","timestamp":857174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[1997,3]]},"DOI":"10.1006\/taap.1996.8080","type":"journal-article","created":{"date-parts":[[2002,9,18]],"date-time":"2002-09-18T22:01:25Z","timestamp":1032386485000},"page":"140-151","source":"Crossref","is-referenced-by-count":5,"title":["Antiviral Efficacy and Toxicity of Ribavirin and Foscarnet Each Given Alone or in Combination in the Murine AIDS Model"],"prefix":"10.1006","volume":"143","author":[{"given":"Rabeea F.","family":"Omar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierrot","family":"Harvie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierrette","family":"Gourde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"D\u00e9sormeaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Beauchamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel G.","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1006\/taap.1996.8080_TO968080C1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0166-3542(95)00018-H","article-title":"In vitro and in vivo enhancement of ddI activity against Rauscher murine leukemia virus by ribavirin","volume":"27","author":"Allen","year":"1995","journal-title":"Antiviral Res."},{"key":"10.1006\/taap.1996.8080_TO968080C2","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1128\/AAC.31.10.1613","article-title":"Ribavirin antagonizes inhibitory effects of pyrimidine 2\u2032,3\u2032-dideoxynucleosides but enhances inhibitory effects of purine 2\u2032,3\u2032-dideoxynucleosides on replication of human immunodeficiency virusin vitro","volume":"31","author":"Baba","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1006\/taap.1996.8080_TO968080C3","first-page":"1140","article-title":"Potentiating effect of ribavirin on thein vitroin vivo","volume":"3","author":"Balzarini","year":"1990","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1006\/taap.1996.8080_TO968080C4","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/infdis\/163.4.869","article-title":"Intermittent, alternating, and concurrent regimens of zidovudine and 2\u2032-3\u2032 dideoxycytidine in the LP-BM5 murine induced immunodeficiency model","volume":"163","author":"Basham","year":"1991","journal-title":"J. Infect. Dis."},{"key":"10.1006\/taap.1996.8080_TO968080C5","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/infdis\/161.5.1006","article-title":"Zidovudine (AZT) reduces virus titer, retards immune dysfunction, and prolongs survival in the LP-BM5 murine induced immunodeficiency model","volume":"161","author":"Basham","year":"1990","journal-title":"J. Infect. Dis."},{"key":"10.1006\/taap.1996.8080_TO968080C6","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0140-6736(90)92253-E","article-title":"Foscarnet and crystals in glomerular capillary lumens","volume":"336","author":"Beaufils","year":"1990","journal-title":"Lancet"},{"key":"10.1006\/taap.1996.8080_TO968080C7","unstructured":"M. G. Bergeron, C. M. Tsoukas, R. Roberts, M. Gent, F. Aoki, J. Conly, J. Falutz, M. Fanning, I. W. Fong, G. Garber, N. Gilmore, S. Landis, D. K. Macfadden, I. Mackie, P. Mansell, A. Marcoux, J. S. G. Montaner, A. Rachlis, B. Romanowski, W. Schlech, C. Sinave, G. Taylor, E. Toma, The Canadian Study Group, 1991, Tolerance of ribavirine in early HIV disease"},{"key":"10.1006\/taap.1996.8080_TO968080C8","unstructured":"M. G. Bergeron, C. M. Tsoukas, J. Securella, F. Aoki, J. Conly, M. Fanning, I. W. Fong, G. Garber, N. Gilmore, S. Landis, D. K. Macfadden, I. Mackie, P. Mansell, A. Marcoux, J. S. G. Montaner, A. Rachlis, B. Romanowski, W. Schlech, G. Sinave, G. Taylor, E. Toma, The Canadian Study Group, 1992, Ribavirin in 462 patients with early HIV disease"},{"key":"10.1006\/taap.1996.8080_TO968080C9","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/infdis\/175.1.176","article-title":"Drug sensitivity of human immunodeficiency virus type-1 isolates after ribavirin therapy","volume":"175","author":"Bernier","year":"1997","journal-title":"J. Infect. Dis."},{"key":"10.1006\/taap.1996.8080_TO968080C10","first-page":"315","article-title":"Acute renal failure induced by foscarnet: 4 cases","volume":"29","author":"Cacoub","year":"1988","journal-title":"Clin. Nephrol."},{"key":"10.1006\/taap.1996.8080_TO968080C11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2165\/00003495-199141010-00009","article-title":"Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis","volume":"41","author":"Chrisp","year":"1991","journal-title":"Drugs"},{"key":"10.1006\/taap.1996.8080_TO968080C12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000167987","article-title":"Foscarnet nephrotoxicity: Mechanism, incidence and prevention","volume":"9","author":"Deray","year":"1989","journal-title":"Am. J. Nephrol."},{"key":"10.1006\/taap.1996.8080_TO968080C13","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/00002030-199508000-00002","article-title":"Encapsulation of foscarnet in liposomes modifies drug intracellular accumulation, in vitro anti-HIV-1 activity, and pharmacokinetics","volume":"9","author":"Dusserre","year":"1995","journal-title":"AIDS"},{"key":"10.1006\/taap.1996.8080_TO968080C14","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/362359a0","article-title":"Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS","volume":"362","author":"Embretson","year":"1993","journal-title":"Nature"},{"key":"10.1006\/taap.1996.8080_TO968080C15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1128\/AAC.33.5.663","article-title":"Combination of 3\u2032-azido-3\u2032deoxythymidine (Zidovudine) and phosphonoformate (Foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replicationin vitro","volume":"33","author":"Eriksson","year":"1989","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1006\/taap.1996.8080_TO968080C16","first-page":"766","article-title":"Ribavirin is an inhibitor of human immunodeficiency virus reverse transcriptase","volume":"38","author":"Fernandez-Larsson","year":"1990","journal-title":"Mol. Pharmacol."},{"key":"10.1006\/taap.1996.8080_TO968080C17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.7326\/0003-4819-122-1-199501010-00004","article-title":"Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease","volume":"122","author":"Fischl","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"10.1006\/taap.1996.8080_TO968080C18","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1128\/AAC.38.3.604","article-title":"Foscarnet for suppression of human immunodeficiency virus replication","volume":"38","author":"Fletcher","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1006\/taap.1996.8080_TO968080C19","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/infdis\/155.3.510","article-title":"Therapeutic efficacy of liposome-encapsulated ribavirin and muramyl tripeptide in experimental infection with Influenza or Herpes simplex virus","volume":"155","author":"Gangemi","year":"1987","journal-title":"J. Infect. Dis."},{"key":"10.1006\/taap.1996.8080_TO968080C20","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1084\/jem.180.6.2199","article-title":"In vivo","volume":"180","author":"Gazzinelli","year":"1994","journal-title":"J. Exp. Med."},{"key":"10.1006\/taap.1996.8080_TO968080C21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1128\/AAC.30.2.201","article-title":"Biochemistry and clinical applications of ribavirin","volume":"30","author":"Gilbert","year":"1986","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1006\/taap.1996.8080_TO968080C22","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/0140-6736(92)91867-8","article-title":"Lack of suppression by ribavirin of HIV viraemia","volume":"339","author":"Gilson","year":"1992","journal-title":"Lancet"},{"key":"10.1006\/taap.1996.8080_TO968080C23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00002030-199601000-00015","article-title":"Selection in vitro of an HIV-1 variant resistant to both lamivudine (3TC) and zidovudine","volume":"10","author":"Goulden","year":"1996","journal-title":"AIDS"},{"key":"10.1006\/taap.1996.8080_TO968080C24","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1128\/JVI.63.3.1223-1231.1989","article-title":"Retrovirus-induced murine acquired immunodeficiency syndrome: Natural history of infection and differing susceptibility of inbred mouse strains","volume":"63","author":"Hartley","year":"1989","journal-title":"J. Virol."},{"key":"10.1006\/taap.1996.8080_TO968080C25","first-page":"1009","article-title":"Ribavirin potentiates the efficacy and toxicity of 2\u2032,3\u2032-dideoxyinosine in the murine acquired immunodeficiency syndrome model","volume":"279","author":"Harvie","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1006\/taap.1996.8080_TO968080C26","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00042560-199608150-00003","article-title":"Antiviral efficacy and toxicity of ribavirin in MAIDS model","volume":"12","author":"Harvie","year":"1996","journal-title":"J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol."},{"key":"10.1006\/taap.1996.8080_TO968080C27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/373123a0","article-title":"Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection","volume":"373","author":"Ho","year":"1995","journal-title":"Nature"},{"key":"10.1006\/taap.1996.8080_TO968080C28","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1128\/AAC.39.6.1376","article-title":"Drug interactions with zidovudine phosphorylation in vitro","volume":"39","author":"Hoggard","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1006\/taap.1996.8080_TO968080C29","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1126\/science.1850169","article-title":"A virus-encoded \u201csuperantigen\u201d in a retrovirus-induced immunodeficiency syndrome of mice","volume":"252","author":"Hugin","year":"1991","journal-title":"Science"},{"key":"10.1006\/taap.1996.8080_TO968080C30","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1542\/peds.93.2.316","article-title":"Zidovudine and didanosine combination therapy in children with human immunodeficiency virus infection","volume":"93","author":"Husson","year":"1994","journal-title":"Pediatrics"},{"key":"10.1006\/taap.1996.8080_TO968080C31","first-page":"S11","article-title":"Review of the toxicities of foscarnet","volume":"5","author":"Jacobson","year":"1992","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1006\/taap.1996.8080_TO968080C32","first-page":"862","article-title":"Effects of foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS","volume":"158","author":"Jacobson","year":"1988","journal-title":"J. Infect. Dis."},{"key":"10.1006\/taap.1996.8080_TO968080C33","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/infdis\/163.6.1219","article-title":"In vivo anti-retroviral effect of combined zidovudine and foscarnet therapy for human immunodeficiency virus infection (ACTG protocol 053)","volume":"163","author":"Jacobson","year":"1991","journal-title":"J. Infect. Dis."},{"key":"10.1006\/taap.1996.8080_TO968080C34","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1128\/AAC.27.6.903","article-title":"Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus in mice","volume":"27","author":"Kende","year":"1985","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1006\/taap.1996.8080_TO968080C35","doi-asserted-by":"crossref","first-page":"6767","DOI":"10.1128\/JVI.68.10.6767-6769.1994","article-title":"In murine AIDS, B cells are early targets of defective virus and are required for efficient infection and expression of defective virus in T cells and macrophages","volume":"68","author":"Kim","year":"1994","journal-title":"J. Virol."},{"key":"10.1006\/taap.1996.8080_TO968080C36","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.4049\/jimmunol.142.4.1144","article-title":"Characteristics of B cell proliferation and activation in murine AIDS","volume":"142","author":"Klinman","year":"1989","journal-title":"J. Immunol."},{"key":"10.1006\/taap.1996.8080_TO968080C37","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1126\/science.7542804","article-title":"Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy","volume":"269","author":"Larder","year":"1995","journal-title":"Science"},{"key":"10.1006\/taap.1996.8080_TO968080C38","first-page":"511","article-title":"Loss of follicular dendritic cells in murine-acquired immunodeficiency syndrome","volume":"73","author":"Masuda","year":"1995","journal-title":"Lab. Invest."},{"key":"10.1006\/taap.1996.8080_TO968080C39","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(84)92060-9","article-title":"Ribavirin suppresses replication of lymphadenopathy-associated virus in cultures of human adult T lymphocytes","volume":"2","author":"McCormick","year":"1984","journal-title":"Lancet"},{"key":"10.1006\/taap.1996.8080_TO968080C40","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/0140-6736(95)90011-X","article-title":"A year of transformation in HIV\/AIDS","volume":"346","author":"Montaner","year":"1995","journal-title":"Lancet"},{"key":"10.1006\/taap.1996.8080_TO968080C41","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/00002030-199207000-00001","article-title":"Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model for AIDS","volume":"6","author":"Morse","year":"1992","journal-title":"AIDS"},{"key":"10.1006\/taap.1996.8080_TO968080C42","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1432-2277.1989.tb01871.x","article-title":"Tubulointestinal nephritis caused by the antiviral agent foscarnet","volume":"2","author":"Nyberg","year":"1989","journal-title":"Transplant Int."},{"key":"10.1006\/taap.1996.8080_TO968080C43","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0163-7258(89)90097-1","article-title":"Antiviral effects of phosphonoformate","volume":"40","author":"\u00d6berg","year":"1989","journal-title":"Pharmacol. Ther."},{"key":"10.1006\/taap.1996.8080_TO968080C44","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1128\/AAC.39.9.1973","article-title":"Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet","volume":"39","author":"Omar","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1006\/taap.1996.8080_TO968080C45","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1006\/taap.1996.0172","article-title":"In vivo toxicity of foscarnet and zidovudine each given alone or in combination","volume":"130","author":"Omar","year":"1996","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1006\/taap.1996.8080_TO968080C46","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1128\/AAC.40.5.1285","article-title":"Synergistic inhibition of human-immunodeficiency-virus isolates (including 3\u2032-azida-3\u2032-deoxythymidine-resistant isolates) by foscarnet in combination with 2\u2032,3\u2032-dideoxyinosine or 2\u2032,3\u2032-dideoxycytidine","volume":"40","author":"Palmer","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1006\/taap.1996.8080_TO968080C47","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/0952-7915(94)90148-1","article-title":"Tracking HIV during disease progression","volume":"6","author":"Pantaleo","year":"1994","journal-title":"Curr. Op. Immunol."},{"key":"10.1006\/taap.1996.8080_TO968080C48","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/362355a0","article-title":"HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease","volume":"362","author":"Pantaleo","year":"1993","journal-title":"Nature"},{"key":"10.1006\/taap.1996.8080_TO968080C49","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJM199501263320402","article-title":"Studies in subjects with long term nonprogressive human immunodeficiency virus infection","volume":"332","author":"Pantaleo","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1006\/taap.1996.8080_TO968080C50","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood.V79.5.1137.1137","article-title":"Liposomal encapsulation of azidothymidine results in decreased hematopoietic toxicity and enhanced activity against murine acquired immunodeficiency syndrome","volume":"79","author":"Phillips","year":"1992","journal-title":"Blood"},{"key":"10.1006\/taap.1996.8080_TO968080C51","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0002-9343(93)90180-W","article-title":"Increased survival of a cohort of patient with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet)","volume":"94","author":"Polis","year":"1993","journal-title":"Am. J. Med."},{"key":"10.1006\/taap.1996.8080_TO968080C52","first-page":"135","article-title":"Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus","volume":"7","author":"Richman","year":"1994","journal-title":"J. Acquir. Immune. Defic. Syndr."},{"key":"10.1006\/taap.1996.8080_TO968080C53","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00002030-199001000-00009","article-title":"A multicenter clinical trial of oral ribavirin in HIV-infected people with lymphadenopathy: Virologic observations","volume":"4","author":"Roberts","year":"1990","journal-title":"AIDS"},{"key":"10.1006\/taap.1996.8080_TO968080C54","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/0042-6822(70)90362-4","article-title":"Plaque assay techniques for murine leukemia viruses","volume":"42","author":"Rowe","year":"1970","journal-title":"Virology"},{"key":"10.1006\/taap.1996.8080_TO968080C55","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S0140-6736(85)92255-X","article-title":"Inhibition of human T-cell lymphotropic virus type IIIin vitro","volume":"1","author":"Sandstr\u00f6m","year":"1985","journal-title":"Lancet"},{"key":"10.1006\/taap.1996.8080_TO968080C56","series-title":"Clinical Applications of Ribavirin","article-title":"Assessment of hematologic effects of ribavirin in humans","author":"Schulman","year":"1984"},{"key":"10.1006\/taap.1996.8080_TO968080C57","unstructured":"H. Senay, S. Trottier, M. Morissette, L. Gareau, M. Belles-Isles, M. Jutras, M. Bergeron, 1991, Ribavirin therapy in patients in early stages of HIV infections"},{"key":"10.1006\/taap.1996.8080_TO968080C58","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/infdis\/172.1.70","article-title":"Drug resistance and heterogenous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy","volume":"172","author":"Shafer","year":"1995","journal-title":"J. Infect. Dis."},{"key":"10.1006\/taap.1996.8080_TO968080C59","series-title":"Studies with a Broad Spectrum Antiviral Agent","first-page":"99","article-title":"Ribavirin: A broad spectrum antiviral agent","author":"Smith","year":"1986"},{"key":"10.1006\/taap.1996.8080_TO968080C60","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0171-2985(11)80269-X","article-title":"Acquired immunodeficiency in murine lymphoproliferative disease: Considerations on pathogenesis","volume":"190","author":"Thacore","year":"1994","journal-title":"Immunobiology"},{"key":"10.1006\/taap.1996.8080_TO968080C61","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.2435003","article-title":"Ribavirin antagonizes the effect of azidothymidine on HIV replication","volume":"235","author":"Vogt","year":"1987","journal-title":"Science"},{"key":"10.1006\/taap.1996.8080_TO968080C62","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/373117a0","article-title":"Viral dynamics in human immunodeficiency virus type 1 infection","volume":"373","author":"Wei","year":"1995","journal-title":"Nature"},{"key":"10.1006\/taap.1996.8080_TO968080C63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/infdis\/169.1.9","article-title":"A randomized pilot study of alternative or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection","volume":"169","author":"Yarchoan","year":"1994","journal-title":"J. Infect. Dis."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X96980801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X96980801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T16:47:41Z","timestamp":1680626861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X96980801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,3]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1997,3]]}},"alternative-id":["S0041008X96980801"],"URL":"https:\/\/doi.org\/10.1006\/taap.1996.8080","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[1997,3]]}}}